

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000704

International filing date: 25 February 2005 (25.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0404187.7
Filing date: 25 February 2004 (25.02.2004)

Date of receipt at the International Bureau: 18 April 2005 (18.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 31 March 2005






26FEB04 E876121-22 000060
P01/7700 0.00-0404187.7 CHEQUE

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

GRF/BP6158539

2. Patent application number

(The Patent Office will fill this part in)

0404187.7

25 FEB 2004

3. Full name, address and postcode of the or of each applicant (underline all surnames)

BIOTRANSFORMATIONS LIMITED
CENTRAL SQUARE SOUTH
ORCHARD STREET
NEWCASTLE UPON TYNE
NE1 3XX

Patents ADP number (if you know it)

8816985001

If the applicant is a corporate body, give the country/state of its incorporation

UNITED KINGDOM

4. Title of the invention

BINDING AGENTS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP

Patents ADP number (if you know it)

109006

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

YES

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form	0
Description	37
Claim(s)	5
Abstract	0
Drawing(s)	0

RM

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for a preliminary examination and search (Patents Form 9/77)

1

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

Graham Forrest

Date 24 February 2004

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

Graham Forrest 0117 926 6411
graham.forrest@mewburn.com

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Binding Agents

Field of the Invention

5 The present invention relates to binding agents, and in particular to binding agents which can be induced to aggregate in response to a specific stimulus. Such reagents find use in both diagnostic and therapeutic applications, *inter alia* for signal amplification, as well as in microfabrication technology where
10 aggregation of components is required.

Background to the Invention

Immunodiagnostic methods have proved to be of great use both
15 within and outside of clinical areas. Food testing, environmental testing and forensic applications are but some of the applications. The robustness, precision and convenience of the methods have led to applications ranging from kits for home use to sophisticated laboratory auto-analysers. In particular,
20 the development of immunometric technologies for large molecular weight analytes has been outstandingly successful.

Immunoassays frequently use antibodies to detect immobilised analyte. These antibodies are conventionally coupled to
25 fluorescent label molecules, or (e.g. in an ELISA) to enzymes capable of producing a colour change by acting on a substrate, to provide a spectrophotometrically detectable readout. Such enzymes include alkaline phosphatase and horseradish peroxidase). Thus the signal produced depends on the number of antibody
30 molecules bound to the immobilised analyte. However typically the signal produced is relatively low per antibody molecule bound. This can lead to a lack of sensitivity, particularly when detecting low concentrations of analyte. Attempts have been made to increase the signal produced by such enzyme-based assays, e.g.
35 by coupling chains of enzyme molecules to detection reagents, or using multiple detection layers. With pre-formed chains of molecules, diffusion and binding to the target may be hindered by

size and other steric effects. Therefore it may be advantageous to use smaller molecules which assemble at or close to the required site. Use of multiple detection layers, added sequentially, is a well used method of increasing the number of detector molecules brought to a site. While it is an effective method of boosting detectable signal it increases complexity, is time consuming, relatively cumbersome with the added disadvantage of introducing the possibility of error. Methods of increasing the amount of detector molecule by secondary precipitation of secondary label have been developed such as Catalysed Reporter Deposition (the Tyramide signal amplification method) in which a first enzyme label gives rise to an insoluble moiety which after precipitation around the site can then be detected by the subsequent addition of a secondary antibody against it. While these methods are capable of increasing signal they also increase complexity with respect to the final user operation concerned, for example, when sequential additions of the various reagents are required. Thus there is a need for further methods of amplifying signals in such assays which are both effective and user-friendly.

Antibodies have also been proposed for targeting therapeutic agents to desired disease sites. This approach is, for example, used for targeting an enzyme capable of converting a prodrug into an active drug to a specific site. An antibody directed against a molecule expressed specifically at that site is administered to the subject. The enzyme may be coupled to that antibody, or to a secondary antibody directed against the first and administered subsequently. This type of therapy is sometimes known as ADEPT (antibody directed enzyme prodrug therapy). Methods of increasing the amount of active enzyme at the desired site, and of increasing the temporal and spatial specificity of activation of the prodrug, are highly desirable. Agents capable of targeted aggregation may find many other possible uses in therapeutic areas where a therapeutic agent is to be targeted to a given site or activated at a selected time.

Summary of the Invention

The present invention provides reagents which can be triggered to self-assemble or aggregate by administration of a suitable stimulus. The stimulus can be administered (or simply encountered by the reagents) in a temporally and spatially specific manner, leading to fine control of aggregation. Reagents of the invention can be used in a wide variety of diagnostic, therapeutic, and other applications.

In a first aspect the present invention provides a binding agent comprising two binding moieties, the binding moieties comprising

(i) a binding member, capable of binding to a binding partner,
and

(ii) the binding partner,

one of said binding moieties being reversibly masked, whereby two such binding agents do not bind one another.

Also provided is a method of causing aggregation of a plurality of binding agents, comprising providing a composition comprising a plurality of binding agents, each comprising two binding moieties, the binding moieties comprising

(i) a binding member for a binding partner, and

(ii) the binding partner,

one of said binding moieties being reversibly masked, whereby said plurality of binding agents do not bind one another,

and unmasking said binding moiety, whereby said plurality of binding agents become capable of binding to one another.

The two binding moieties are preferably covalently linked, and so form part of the same molecule. However the binding agent may also be a molecular complex held together by non-covalent interactions, with the two binding moieties being located on
5 different components of the complex. Reference herein to a binding agent molecule should be construed accordingly.

Thus in this aspect of the invention the binding agent comprises two binding moieties which in isolation are capable of binding to
10 one another, and hence are capable of inducing aggregation of a plurality of identical such binding agents. One (or more) of these moieties is masked so that such aggregation cannot take place until that moiety is unmasked. These complementary binding moieties are referred to herein as a binding member and a binding
15 partner.

However, the terms "binding member" and "binding partner" should not be taken to imply any particular structural or functional relationship other than the capacity of each to bind the other.
20 Furthermore, it will be understood that a moiety referred to as a binding member in one context may equally be referred to as a binding partner in another context.

Typically the binding member and binding partner are members of a
25 specific binding pair, as described in more detail below. Suitable binding pairs include, but are not restricted to, antibody and cognate antigen, receptor and ligand, avidin/streptavidin and biotin, nucleic acids, carbohydrates and lectins, etc..

30 Preferably, the moieties of a single binding agent cannot interact with one another after the binding moiety is unmasked. Such intra-molecular interactions are generally undesirable because they will tend to reduce the potential for inter-
35 molecular aggregation. Typically, then, the binding moieties will be spaced apart such that they are sterically incapable of interacting with one another, but are capable of interacting with

their respective complementary binding moieties on other binding agents.

5 Unmasking the reversibly masked binding moiety may be regarded as activation of that moiety, or activation of the binding agent in general.

10 The appropriate binding moiety may be masked by a masking element located at or adjacent that binding moiety. The masking element may prevent binding to the cognate binding moiety via steric interference, electrostatic repulsion or any other suitable mechanism.

15 A detachable masking element may be provided; for example the masking element may be coupled to the binding agent via a selectively cleavable group or bond.

20 The masking element may be cleavable from the binding agent by a variety of techniques, including, but not limited to irradiation, oxidation, reduction, pH change, or enzymatic cleavage. The cleavage method may be selected appropriately depend upon the application for which the binding agent is to be used.

25 It may be desirable to design the binding agent such that the binding moiety is unmasked by action of a particular enzyme. For example, it may be desirable that the binding moiety is unmasked by an enzyme secreted by a particular tumour cell so that the binding (and/or effector) properties of the binding agent are activated only in proximity to that cell type. Suitable enzymes
30 include proteases, such as metalloproteases, which are secreted by a variety of tumour cells, especially metastatic tumour cells.

35 Use of enzymatic cleavage as an activation mechanism may enable a chain reaction of binding agent activation to take place, wherein one activated binding agent is capable of activating a further binding agent, and so on. Particularly useful are binding agents comprising an inactive enzyme (e.g. a proenzyme or zymogen),

- wherein the active form of the enzyme is capable of converting its own inactive form to its active form, e.g. by cleaving the propeptide from a proenzyme. Typically the binding agent will comprise a binding moiety which binds preferentially to the active form of the enzyme, and preferably does not bind, or substantially does not bind, to the inactive form. In such cases, the mask may be seen as the element causing the inactivity of the enzyme, e.g. the propeptide of a proenzyme.
- 10 An example of a suitable proenzyme is chymotrypsinogen, which is activated to chymotrypsin by cleavage of its propeptide. Chymotrypsin is itself capable of converting chymotrypsinogen to chymotrypsin.
- 15 Alternatively, the masked binding moiety may be unmasked by a conformational change in the binding agent. This may create a new conformation in the binding agent which can be bound by the binding member, or may expose a part of the binding agent previously masked or screened (e.g. sterically). Thus the binding moiety may be unmasked by a conformational change in the binding agent, whereby said binding member or said binding partner is exposed. Conformational change may take place along with, or as a result of, another method of activation. For example, where a proenzyme is used as a binding moiety as described above, the complementary binding moiety may recognise a particular conformation which is generated only on cleavage of the propeptide. An antibody capable of binding specifically to chymotrypsin but not to chymotrypsinogen may thus be used in combination with chymotrypsinogen.
- 30 Thus the mask may be removed or reversed by a conformational change in the binding agent, whereby said binding moiety is exposed.
- 35 Irradiation is a further potential activation mechanism, which is particularly preferred, especially in therapeutic applications, because of the tight spatial and temporal control over activation

which it provides. It is possible to administer a binding agent to a subject systemically or locally, and activate the binding agent very specifically e.g. by means of a laser. This may reduce undesirable activation elsewhere in the body.

5

The binding agent will typically comprise an effector member. The nature and identity of the effector will depend upon the intended use of the binding agent. The binding agents may be used in any application in which it is desirable to cause a
10 localised increase in concentration of a particular effector, whether in vivo or in vitro.

15

The binding agents described herein may be used to provide or amplify a signal, in an assay for determining the presence or
15 concentration of an analyte at a particular site or in a sample. Such assays include biological, biochemical, or immunological assays performed in vitro, as well as diagnostic tests practised on an individual in vivo.

20

In such embodiments, the effector may comprise a signal generating means. Examples include label moieties, such as radiolabels or fluorescent labels. Alternatively the effector may comprise an enzyme capable of acting on a substrate to
25 produce a detectable readout. This may include acting on a substrate to produce a spectrophotometrically detectable change such as a colour change. Such enzymes include alkaline phosphatase and horseradish peroxidase. Other possibilities will be apparent to the skilled person.

30

In other embodiments the effector member may have a binding functionality. For example it may be capable of binding to a target cell type. In particular embodiments it may be capable of inducing aggregation or activation of one or more particular cell types at the site of binding agent aggregation. Thus the
35 effector member may be capable of binding to the surface of a cell, and optionally activating that cell type. Thus the effector member may bind to, and optionally be an agonist of, a

cell surface molecule. For example the effector may be a receptor, co-receptor, ligand or another type of agonist such as an antibody. The cell may be a cell of the immune system, such as a T cell or natural killer (NK) cell. For example, the effector may be an anti-CD3 antibody capable of activating T cells at the site of binding agent aggregation. Such effectors may be useful therapeutically, e.g. for activation of an immune response. This may be useful for treatment of cancers or infections by intracellular parasites, such as viruses, malaria, etc..

Effectors capable of binding to the surface of a target cell may also be used to localise the binding agents to that particular cell type, e.g. to target a therapeutically useful effector to that cell type. Binding agents such as antibodies which are capable of binding to cell-specific antigens are particularly useful here. Examples include binding agents for tumour specific antigens, and parasite antigens, such as viral antigens.

Other effectors which may be therapeutically useful include drug and prodrug molecules, as well as enzymes for converting prodrugs to an active form. Such enzymes include phosphatases, carboxypeptidase, beta-glucosidase, beta-lactamases, amidase, cytosine deaminase and nitroreductase. These may also be useful in the treatment of infections or cancers. Binding agent aggregation may be induced at the site of a tumour or infection, e.g. by irradiation, allowing localised concentration of the relevant effector.

The effector moiety may also be reversibly masked or inhibited to prevent it exerting its function until activated. The effector moiety may be masked by the same means as the binding member/partner, or by a different means. Thus the same or different stimuli may be needed to activate aggregation and effector functions.

The invention further provides methods of making binding agents as described herein. Preferred methods comprise the steps of:

- (i) providing a first component comprising a binding member,
5 capable of binding to a binding partner; and
- (ii) providing a second component, comprising said binding partner;
- 10 wherein one of said binding member and binding partner is reversibly masked such that said binding member or partner is prevented from binding to the other; and
- iii) contacting said first component with said second component
15 such that they become associated with one another.

The method may comprise the further step of reversibly masking the relevant binding member or partner.

- 20 The first and second components may be associated by covalent bonds such that they form a single molecule. For example, conventional conjugation reagents may be used to form a covalent conjugate between the two components. Alternatively the components may be associated with one another non-covalently,
25 e.g. to form a complex held together by non-covalent interactions, such as antibody-antigen or avidin-biotin interactions.

- Each of said first and second components may comprise a plurality
30 of said binding members or partners, only a fraction of which are masked. Thus they may be joined together via interaction between unmasked binding members and partners, as long as the resulting complex or molecule still comprises at least one free binding partner and at least one free binding member, one of which is
35 reversibly masked.

For example, a single component complex may be generated by partially masking an avidin molecule, so that some, but not all, of its four biotin binding sites are masked and cannot bind biotin. The partially masked biotin is then contacted with a biotinylated effector molecule (e.g. alkaline phosphatase for use in amplifying a signal in an immunoassay). This leads to the formation of complexes which will themselves aggregate when the remaining avidin binding sites are unmasked.

The invention also extends to systems having two or more binding agent components. Where two or more components are used, any one binding agent need not carry both a binding member and its respective binding partner. Instead, each binding agent should carry at least two binding moieties, each being the binding partner for a binding member present on another component of the system (another binding agent). As implied above and elsewhere, the terms "binding member" and "binding partner" here can be regarded as interchangeable. Thus a "binding member" on a first component could equally be referred to as the "binding partner" of a complementary "binding member" on another component of the system.

Thus in a further aspect the present invention provides a composition comprising at least two populations of binding agents, each population having at least two binding members for respective binding partners, each of said binding partners being present on another of said populations of binding agents, wherein a binding member of at least one of said populations is reversibly masked, whereby said one population does not bind the population carrying the respective binding partner.

Also provided is a method of causing aggregation of a plurality of binding agents, comprising

obtaining a composition comprising at least two populations of binding agents, each population having at least two binding members for respective binding partners, each of said binding

partners being present on another of said populations of binding agents, wherein a binding member of at least one of said populations is reversibly masked, whereby said one population does not bind the population carrying the respective binding partner,

and unmasking said binding member, whereby said one population becomes capable of binding the population carrying the respective binding partner.

Also provided is a kit comprising at least two populations of binding agents, each population having at least two binding members for respective binding partners, each of said binding partners being present on another of said populations of binding agents, wherein a binding member of at least one of said populations is reversibly masked, whereby said one population does not bind the population carrying the respective binding partner.

Each population comprises a plurality of a particular species of binding agent.

The binding members and partners of each binding agent may be the same or different.

Each population of binding agents may have one or more of its binding moieties masked. Each is preferably unmasked by the same mechanism.

Preferred methods, kits and compositions comprise only two species of binding agent, in which each binding agent has (at least) two binding members/binding partners capable of binding to their complementary partner/member on the other binding agent. Thus in a preferred embodiment, each of the binding partners is present on the same other population of binding agents. Examples of two-component systems include

(i) an antibody having two antigen binding sites, in combination with an antigen molecule having at least two epitopes recognised by the antibody. Either the antigen binding sites or the cognate epitopes, or both, may be reversibly masked; (ii) an avidin molecule (having four biotin binding sites), in combination with a molecule conjugated to two or more biotin moieties. Typically, the avidin binding sites are reversibly masked to prevent interaction with biotin before activation. This may be regarded as a two-component version of the single-component binding agent described above which comprises a complex of partially masked avidin with a multiply biotinylated effector molecule.

The invention also encompasses methods, kits and compositions comprising three or more species of binding agent, in which at least one species is reversibly masked to prevent binding to at least one of the other species.

The multiple component systems, compositions, kits etc., may have masking and activation mechanisms, effector members etc. as described for the single component systems.

Systems, compositions and kits having two or more binding agents which associate together preferably contain substantially stoichiometrically equal amounts of each member of a particular binding pair. If one member is present in large excess, then the desired cross-linking and aggregation of binding agents is unlikely to occur. Instead, activation will lead to the formation of a large number of very small complexes, in which the binding agents carrying the binding member present in excess will (at most) be able to bind only one or a few of the binding agents carrying the respective binding partner. Efficient cross-linking requires that each binding agent associates with at least two other binding agents.

The methods of the invention may be applied in vitro or in vivo. Aggregation of binding agents may take place in solution or on a

surface, e.g. a cell surface or the surface of a solid support such as a microtitre plate.

Where aggregation takes place on a surface, a binding member or
5 binding partner may be present on that surface to enable a first binding agent to become associated with that surface. The binding agents may therefore aggregate at a specific focus, e.g. on a particular molecule present on or bound to that surface. Thus the methods of the invention may comprise the step of
10 providing a focus for aggregation of the binding agents.

Typically the focus is a molecule comprising a moiety capable of binding to one of the binding agents, so that when activated (unmasked), the binding agents will aggregate at the focus.

15 This binding may be effected via one of the binding moieties present on the binding agents, i.e. a binding member or binding partner, or via an effector member of the binding agent, or any other part of the binding agent molecule. In preferred
20 embodiments the focus for aggregation is a molecule which itself comprises at least one of the binding moieties present on the binding agents, i.e. a binding member or binding partner.

Additionally or alternatively, the method may comprise the step
25 of providing a source of an agent capable of unmasking the masked binding moiety of the binding agent. This is particularly applicable where aggregation is not required to take place on a particular surface; but simply in the vicinity of a particular site, e.g. in free solution.

30 For example, the present invention provides means for causing targeted aggregation of binding agents carrying effector members having therapeutic properties, such as stimulation of the immune system, activation of prodrugs, etc. It may be desirable for
35 such binding agents to aggregate in the vicinity of a disease site (e.g. a tumour, a parasitised cell, etc.), in order to increase activation of the immune system or a prodrug at that

site. The binding agent may be designed such that its aggregation is triggered by an agent produced by or at the disease site, such as a viral enzyme produced by an infected cell, or a metalloprotease produced by a tumour cell. Thus the disease site itself may be regarded as the source of the activating agent.

The present invention further provides binding agents and compositions as described herein for use in a method of medical treatment, for example in the elimination or reduction of parasitised or tumour cells. Also provided is the use of binding agents and compositions as described herein in the manufacture of a medicament, e.g. for the treatment of cancer, or an infection by an intracellular parasite such as a virus or malaria.

Detailed Description of the Invention

The invention provides materials and methods for producing aggregates of binding agents in a temporally and/or spatially specific manner by a specific stimulus resulting in the removal of a mask which prevents interaction between the binding agents. These materials and methods can be applied in numerous diagnostic and therapeutic settings in which fine control of aggregation is desirable.

Specific Binding Pairs

The binding moieties described herein, i.e. a binding member and its complementary binding partner, preferably constitute a specific binding pair.

The term "specific binding pair" is used to describe a pair of molecules comprising a specific binding member (sbm) and a binding partner (bp) therefor which have particular specificity for each other and which in normal conditions bind to each other in preference to binding to other molecules. Examples of specific binding pairs are antibodies and their cognate

epitopes/antigens, ligands (such as hormones, etc.) and receptors, avidin/streptavidin and biotin, lectins and carbohydrates, and complementary nucleotide sequences.

- 5 Enzymes may bind specifically to their substrate or to modulators such as inhibitors and activators, either competitive or allosteric, which may exert their physiological effects by binding to the active site or elsewhere on the enzyme molecule. Thus enzymes may be used as binding members in the present
- 10 invention, although when the binding partner is a substrate for the enzyme, the enzyme may be inactivated so that it does not structurally alter or modify the binding partner. This may be achieved by mutagenesis (e.g. of a catalytically important residue at the active site), by removal of a cofactor, etc.
- 15 Alternatively the enzyme may be unable to act on the substrate because of the absence in the assay medium of another required molecule such as a cosubstrate.

- Molecular imprints may also be used as binding members. These
- 20 may be made by forming a plastic polymer around a target analyte, extracting the analyte from the formed polymer, and then grinding the polymer to a fine powder, as described in Nonbiological Alternatives to Antibodies in Immunoassays; Principles and Practice of Immunoassay (second edition) Chapter 7 pp 139-153 Ed
- 25 CP Price & DJ Newman (1997).

- Aptamers are DNA or RNA molecules, selected from libraries on the basis of their ability to bind other molecules. Aptamers have been selected which can bind to other nucleic acids, proteins,
- 30 small organic compounds, and even entire organisms, and so may also be used in the present invention.

The skilled person will be able to think of many other examples and they do not need to be listed here.

- 35 The term "specific binding pair" is also applicable where either or both of the specific binding member and binding partner

comprise just the binding part of a larger molecule. Thus in the context of antibodies, a specific binding member may comprise just a domain of an antibody (antibody binding domain) which is able to bind to either an epitope of an antigen or a short
5 sequence which although unique to or characteristic of an antigen, is unable to stimulate an antibody response except when conjugated to a carrier protein.

It has been shown that fragments of a whole antibody can perform
10 the function of binding antigens. The term "antibody" is therefore used herein to encompass any molecule comprising the binding fragment of an antibody. Examples of binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CH1
15 domains; (ii) the Fd fragment consisting of the VH and CH1 domains; (iii) the Fv fragment consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. et al., Nature 341, 544-546 (1989)) which consists of a VH
20 domain; (v) isolated CDR regions; (vi) F(ab')₂ fragments, a bivalent fragment comprising two linked Fab fragments (vii) single chain Fv molecules (scFv), wherein a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to form an antigen binding member (Bird et al, Science, 242, 423-426, 1988; Huston et al, PNAS USA, 85, 5879-5883, 1988).

25 Bispecific antibodies may also be used in the present invention. These include bispecific single chain Fv dimers (PCT/US92/09965) and "diabodies", i.e. multivalent or multispecific fragments constructed by gene fusion (WO94/13804; P. Holliger et al., Proc.
30 Natl. Acad. Sci. USA 90 6444-6448, 1993).

Diabodies are multimers of polypeptides, each polypeptide comprising a first domain comprising a binding region of an immunoglobulin light chain and a second domain comprising a
35 binding region of an immunoglobulin heavy chain, the two domains being linked (e.g. by a peptide linker) but unable to associate with each other to form an antigen binding member: antigen

binding members are formed by the association of the first domain of one polypeptide within the multimer with the second domain of another polypeptide within the multimer (WO94/13804).

- 5 An example of a bispecific antibody which can be used as a binding agent according to the present invention is one having two antibody fragments in which a first antigen binding site is directed against a particular antigen, while a second antigen binding site is an anti-idiotypic site specific for the first
10 antigen binding site. Such a bispecific antibody will aggregate when neither of the antigen binding sites is masked, and will also bind to the antigen for which the first fragment is specific. Alternatively the second binding site could be
15 specific for an epitope on the first antibody fragment outside the antigen binding site. The first antigen binding site may serve as the effector portion of the molecule, or a further effector portion may be present.

Masking and activation mechanisms

20

The binding agent(s) must be prevented from interacting with one another before the activating stimulus is delivered. Thus binding members/partners are reversibly masked to prevent interaction with their complementary binding moiety.

25

- The mask may be provided by a detachable masking element. The masking element may be coupled to the binding agent via a selectively cleavable bond group or bond. The masking element may be located at or adjacent the binding member or binding
30 partner. It may prevent binding to the cognate binding moiety via steric interference, electrostatic repulsion or any other suitable mechanism.

35

The binding moiety may be unmasked by selective cleavage of the masking element from the binding agent. A variety of techniques may be used, including, but not limited to irradiation (photolysis), oxidation, reduction, pH change, or enzymatic

cleavage. The cleavage method may be selected appropriately depend upon the application for which the binding agent is to be used.

- 5 Use of enzymatic cleavage may enable a chain reaction of binding agent activation to take place. For example, a binding agent may comprise a catalytically inactive proenzyme (or zymogen) form of a protease, coupled to an antibody directed against the active protease but incapable of binding to the proenzyme. No
- 10 aggregation of this binding agent will occur until the zymogen is activated by cleavage of its propeptide (e.g. by the presence of a catalytic amount of the active enzyme). The activated enzyme will then be capable of both activating the proenzyme of other binding agents and of binding to the antibody portion of the
- 15 binding agent. Thus a chain reaction of activation and aggregation will be initiated. Suitable proenzymes include chymotrypsinogen.

- In preferred embodiments the selectively cleavable group is
- 20 cleavable by irradiation, e.g. by UV, infra-red, X-ray or visible irradiation.

- Thus the binding member/partner is preferably masked to prevent interaction with its complementary binding moiety by a
- 25 photocleavable moiety. Such photocleavable moieties are well known in the art. Protein binding agents can be suitably derivatised by means of appropriate reagents which couple to hydroxy or amino residues. Thus phosgene, diphosgene or DCCI (dicyclohexyl carbodiimide) may be used to generate
- 30 photocleavable esters, amides, carbonates and the like from a wide variety of alcohols. Nitrophenyl derivatives may be used in this context. Substituted arylalkanols may be used, such as nitrophenyl methyl alcohol, 1-nitrophenylethan-1-ol, and substituted analogues. Thompson et al. (Biochem. Biophys. Res.
- 35 Com. 201, 1213-1219 (1994) and Biochem. Soc. Trans. 225S, 23 (1995)) describe reversible inhibition of protein function by addition of 1-(2-nitrophenyl)-ethyl (NPE) moieties. Further

photocleavable moieties will be well known to the skilled person, e.g. from "Biological Applications of Photochemical Switches", H. Morrison (ed.), Bioorganic Photochemistry Series, Volume 2, J. Wiley & Sons. (see especially Chapter 1, section 4, pages 34 to 50).

Alternatively, the mask may be removed by a conformational change in the binding agent. This may create a new conformation in the binding agent which can be bound by the binding member, or may expose a part of the binding agent previously masked or screened (e.g. sterically). Thus the mask may be reversed by a conformational change in the binding agent, whereby said binding member or said binding partner is exposed. Conformational change may take place along with, or as a result of, another method of activation. For example, in the proenzyme example described above, the antibody may recognise a particular conformation which is generated only on cleavage of the propeptide.

Effector members

As described above, the nature and identity of the effector will depend upon the intended use of the binding agent.

Applications of the methods and binding agents described include signal generation and amplification. This may be particularly useful in assays for determining the presence or concentration of an analyte in a sample. Such assays typically employ agents having binding sites capable of specifically binding to the analyte of interest in preference to other molecules. Examples include antibodies, receptors and other molecules capable of specifically binding the analyte of interest. Conveniently, the binding agents are immobilised on solid supports, e.g. at defined, spatially separated locations, to make them easy to manipulate during the assay.

The sample is generally contacted with the binding agent(s) under appropriate conditions which allow the analyte in the sample to bind to the relevant agent(s).

- 5 The fractional occupancy of the binding sites of the binding agent(s) is then determined either by directly or indirectly labelling the analyte or by using a developing agent or agents to arrive at an indication of the presence or amount of the analyte in the sample. Typically, the developing agents are directly or
10 indirectly labelled (e.g. with radioactive, fluorescent or enzyme labels, such as horseradish peroxidase) so that they can be detected using techniques well known in the art.

15 Directly labelled developing agents have a label associated with or coupled to the agent. Indirectly labelled developing agents may be capable of binding to a labelled species (e.g. a labelled antibody capable of binding to the developing agent) or may act on a further species to produce a detectable result.

- 20 Thus, radioactive labels can be detected using a scintillation counter or other radiation counting device, fluorescent labels using a laser and confocal microscope, and enzyme labels by the action of an enzyme label on a substrate, typically to produce a colour change. In further embodiments, the developing agent or
25 analyte is tagged to allow its detection, e.g. linked to a nucleotide sequence which can be amplified in a PCR reaction to detect the analyte. Other labels are known to those skilled in the art are discussed below. The developing agent(s) can be used in a competitive method in which the developing agent competes
30 with the analyte for occupied binding sites of the binding agent, or non-competitive method, in which the labelled developing agent binds analyte bound by the binding agent or to occupied binding sites. Both methods provide an indication of the number of the binding sites occupied by the analyte, and hence the
35 concentration of the analyte in the sample, e.g. by comparison with standards obtained using samples containing known concentrations of the analyte.

There is also an increasing tendency in the diagnostic field towards miniaturisation of such assays, e.g. making use of binding agents (such as antibodies or nucleic acid sequences) immobilised in small, discrete locations (microspots) and/or as arrays on solid supports or on diagnostic chips. These approaches can be particularly valuable as they can provide great sensitivity (particularly through the use of fluorescent labelled reagents), require only very small amounts of biological sample from individuals being tested and allow a variety of separate assays can be carried out simultaneously. This latter advantage can be useful as it provides an assay employing a plurality of analytes to be carried out using a single sample. Examples of techniques enabling this miniaturised technology are provided in WO84/01031, WO88/1058, WO89/01157, WO93/8472, WO95/18376/ WO95/18377, WO95/24649 and EP 0 373 203 A.

The methods, compositions and binding agents of the present invention can be used in numerous ways either to provide or to increase or amplify the signal obtained in such assays. These applications will be readily apparent to the skilled person.

Typically, for signal generation or amplification purposes (e.g. in assays and diagnostic applications), the effector comprises a signal generating means such as a label molecule, e.g. a radioactive, fluorescent, chemiluminescent or enzyme label, so that it can be detected using techniques well known in the art. Alternatively the binding agent may be indirectly labelled via a further labelled species (e.g. a labelled antibody capable of binding to the binding agent) in which case the effector may be viewed as that part of the binding agent with which the further labelled species interacts.

Different populations of binding agents in the same system may carry different label molecules. In preferred embodiments these different label molecules interact when their binding agents

aggregate to give a different signal to that produced by the individual labels on the unaggregated binding molecules.

5 The signal generation methods described in The Immunoassay Handbook (Second Edition) Ed D Wild published by the Nature Publishing Group (2001) are particularly appropriate. Of particular application are those homogeneous systems described in Chapter 11 (E.F. Ullman). Scintillation Proximity Assay (SPA) (with for example a weak alpha or beta-emitter and a fluorophore) and Enzyme Channelling (with for example glucose oxidase and peroxidase) provide particularly attractive systems for use in the methods described. In these methods the binding agents may be labelled with complementary components of the detection system such that when they aggregate the two components are brought
10 closely enough together to produce a detectable signal but when in solution prior to activation no such association occurs and thus no signal is produced.

20 Preferred enzyme labels are those capable of acting on a substrate to produce a detectable change. In preferred embodiments the change is detectable by spectrophotometric methods, e.g. a colour change. Alkaline phosphatase and horseradish peroxidase are well-known examples of such enzymes but the skilled person will be aware of other equally suitable
25 examples.

The binding agents of the invention may also be used to generate or amplify a signal in a diagnostic method practised in vivo, e.g. to detect the presence of a tumour in a patient. For
30 example, a tumour specific antibody may be administered to the patient in order to bind the tumour if present. An enzyme conjugated to the antibody may be capable of activating a labelled binding agent according to the invention in order to provide localisation of a detectable signal at the site of the
35 tumour.

Other types of effector may be useful for therapeutic applications. The effector may play a part in localising the binding agent to a desired site and/or for activating particular biological effector functions. Binding agents may carry two or
5 more of the same or different kinds of effector member.

Depending on the particular application, any biologically active molecule may be useful as an effector member. These include signalling molecules and other molecules capable of inducing a
10 cellular response, such as a ligand for a cell surface receptor (e.g. a hormone, growth factor, cytokine etc.), molecules having binding functionalities, such as antibodies, lectins, receptors for ligands as described above, coreceptors, etc. and molecules having other biological effector functions such as enzymes, etc..

15 The present invention allows binding agents comprising such effectors to aggregate in response to a given stimulus, rapidly increasing the density of effector at the point of stimulus.

20 Molecules capable of binding to cell surface receptors may be used as effectors to induce particular responses from those cells. For example by cross-linking receptors on the surface of immune cells, those cells may be activated. Thus, particularly preferred are effectors capable of binding and optionally
25 activating cells of the immune system. The examples below describe use of anti-CD3 antibodies to activate T cells, prompting them to proliferate and produce pro-inflammatory cytokines such as IL-2. When these antibodies are in individual form in solution they typically have little or no effect on T
30 cells because of the limited scope for cross-linking of cell surface receptors which free individual antibodies provide. When used as part of binding agents of the present invention, though, these agents may be used to stimulate an immune response at a particular site in the body.

35 Further effector members include enzymes capable of activating prodrugs as their effector members. Phosphatases, particularly

alkaline phosphatase, can be used to convert phosphorylated prodrugs into a more cytotoxic de-phosphorylated form. For example, etoposide phosphate, mitomycin phosphate and doxorubicin phosphate may be dephosphorylated to yield etoposide, mitomycin and doxorubicin respectively. Carboxypeptidase, particularly G2, may be used to activate prodrugs in which a glutamic acid residue is used to inactivate the drug molecule. Beta-glucosidase can be used to produce cyanide from amygdalin. Beta-lactamases, such as penicillinase and cephalosporinase can be used to generate vinblastine or DAVLBHYD by hydrolysing the beta-lactam ring of a pro-drug comprising the drug linked to cephalosporin. Amidases, such as penicillin amidases, such as phenoxymethyl penicillin amidase can be used to produce melphalan or doxorubicin from their acetamide (e.g. phenoxylacetamide) derivatives. Cytosine deaminase can convert S-fluorocytisine to 5-fluorouracil. Nitroreductase, e.g. from E. coli, can be used to convert CB 1954 to an active alkylating agent.

The binding agent and prodrug may be administered to the subject separately or together, with activation of the drug taking place only at the desired site.

Alternatively the concentration of a drug at a particular site may be increased simply by using the drug molecule itself as the effector member, or by using an effector member having a particular affinity for the drug (e.g. an antibody against the drug).

An effector capable of binding to an antigen on the surface of a platelet may be used to promote platelet aggregation and thrombus formation at a site where clotting is desirable.

Effectors capable of binding to infectious agents may be used to cause aggregation of those agents, so reducing virulence, infectivity or pathogenicity, or increasing speed of clearance of the infectious agents by the immune system.

Effectors capable of binding to target cells may be used to localise one or more binding agents to that cell type. Such effectors may be used to localise binding agents carrying therapeutic effectors as described to the target cell type.

- 5 Examples include binding agents (e.g. antibodies) directed against tumour specific antigens or parasite antigens such as viral proteins.

- 10 Binding agents according to the present invention may be used to form scaffolds for tissue engineering. This may be achieved by use of effectors capable of binding to one or more types of cell and/or extracellular matrix molecules.

- 15 The nature of the stimulus required to unmask the binding agent and trigger activation will control where and when aggregation occurs. For example, a photo-activatable binding agent may be induced to aggregate by local application of laser illumination. Alternatively a binding agent activatable by a metalloprotease may be activated in the locality of a metastatic tumour secreting
20 that enzyme. This would not require any external stimulus to be applied after administration of the binding agent to the subject, but activation of the immune system would only occur at the disease site.

25 Examples

Alkaline phosphatase signal amplification reagent

- 30 An antibody directed against alkaline phosphatase may be coupled to one or more alkaline phosphatase molecules with which it is immunologically reactive. Either the antigen binding site, the alkaline phosphatase, or both, may be masked e.g. by coating with a photocleavable moiety.

- 35 Such a reagent may be made by coating (masking) the antibody with e.g. NPE, as described by Thompson et al. (see above), and then conjugating it to alkaline phosphatase using conventional

coupling techniques well known to those skilled in the art. This reagent may find application in immunoassays such as ELISAs in which a secondary antibody coupled to alkaline phosphatase (AP) is used. Instead of developing the assay by adding AP substrate after binding of the secondary antibody, the binding agent described above is added under conditions in which it is not activated. For example, where NPE is used as a coating reagent, simply keeping the reagent away from strong UV irradiation will keep it inactive. It is not generally necessary to use the reagent in the dark.

The binding agents are incapable of binding to either the immobilised AP or to each other until activated by irradiation. After irradiation it will aggregate on the immobilised AP. This will greatly increase the amount of AP immobilised at each bound secondary antibody, and will greatly increase the signal obtained when the assay is developed by addition of colour substrate. This achieves a number of benefits over conventional assays, including reduced development time and increased signal to noise ratio. Use of reagents of this sort is of particular benefit where small-scale assay systems are used, such as micro- or nano-scale array systems.

Example 1

Generation of NPE-cloaked Alkaline phosphatase - anti-Alkaline Phosphatase conjugate

A conjugate was prepared containing alkaline phosphatase conjugated to an NPE-coated anti-alkaline phosphatase antibody.

Alkaline Phosphatase (Biogenesis) was dialysed against 0.1M phosphate pH7.5 containing 0.1M NaCl. Its final concentration was 0.92 mg/ml.

Anti-Alkaline Phosphatase was obtained from Zymed. 2mg of this antibody in 4ml buffer was dialysed against 0.1 M Bicarbonate. Its final volume was 4.5ml. 1.5 ml was retained as control.

- 5 NPE (1-(2-nitrophenyl)ethanol) (11mg) was reacted with 7.8µl diphosgene in 250µl dry dioxan in the presence of 5.2µl pyridine catalyst. A white precipitate immediately formed following which the mixture was left for 15 minutes before unreacted materials were evaporated away in a stream of nitrogen. The 1-(2-
- 10 nitrophenol)ethoxycarbonyl chloride was resuspended in 250µl dioxan for use.

- 10µl of the carbonyl chloride (NPE-COCl) product were added to 2 x 1.5ml aliquots of the antibody and left for 4h. The solution
- 15 was then dialysed overnight against 50mM phosphate pH 7.5 and then centrifuged at 13K in a micro-centrifuge for 10min. The final concentration of NPE-anti Alkaline Phosphatase was 0.26 mg/ml. OD 0.398 (giving an average of 7.2 residues of NPE per antibody molecule).

- 20 3-(2-pyridylthio)propionic acid N-hydroxy succinimide ester (SPDP, Pierce), a bifunctional crosslinker, was used to conjugate the cloaked/coated antibody to the alkaline phosphatase.

- 25 1ml of each of the Alkaline Phosphatase (0.5mg/ml) and the NPE-coated anti-Alkaline Phosphatase antibody(0.26 mg/ml) in 0.05M phosphate buffer pH 7.5 were separately derivatised by the addition of a 60 fold molar excess of SPDP (60µl and 30µl respectively of 1.26mg/ml SPDP in ethanol) for 2h. Excess SPDP
- 30 was then removed from each component on P10 desalting columns. The SPDP-Alkaline Phosphatase was then reduced by the addition of 100µl 0.5M Dithiothreitol (DTT) for 30 minutes and the excess DTT was removed on another P10 column. The reduced SPDP-AP was then immediately added to the unreduced SPDP-derivatised NPE-anti-AP
- 35 antibody and the mixture was left overnight at 20°C to allow cross-linking to occur. The final protein concentration was 0.2 mg/ml.

Use of NPE-coated anti-AP-AP reagent in an amplified assay for alkaline phosphatase

5 Wells of a 96 well Elisa plate each received 100 μ l of an alkaline phosphatase sample (comprising 0.01 μ g/ml alkaline phosphatase in bicarbonate buffer pH9.6) and incubated overnight at 4°C. Following incubation the plate was blocked with 100 μ l 0.5% BSA in coating buffer for 1 hour. The plate was then washed three times
10 in PBS-Tween.

100 μ l of the NPE-coated anti-AP-AP conjugate (0.01mg/ml) was added to the wells, which were then UV irradiated for 0, 2, 5 and 10 minutes. After a further 1h incubation the plate was washed
15 and p-nitrophenyl phosphate substrate was added. Colour development was monitored at OD 405nm. A greater than six-fold increase was obtained in the detection of the sample alkaline phosphatase after UV irradiation. The results are given in the table below.

20

Irradiation time (minutes)	OD 405nm (after 1h)	OD 405nm minus background (0.05)
0	0.30	0.25
2	1.43	1.38
5	1.62	1.57
10	1.68	1.63

Example 2

25 *Generation of NPE-coated Biotin-Alkaline Phosphatase -Avidin conjugates*

A conjugate containing biotinylated alkaline phosphatase linked to NPE-coated avidin was prepared.

Coating of Avidin with NPE

Avidin (from egg white, Sigma Chemical Co Ltd) at a concentration of 1mg/ml was dialysed against 0.1M bicarbonate pH8.3 for 5h during which the volume increased to 1.5ml. 0.5ml was retained as control.

NPE-COCl was prepared as described in example 1 above. 50 l NPE-COCl was added to the remaining 1ml Avidin and left to gently rotate for 5h. It was then dialysed against 10mM phosphate pH 7.4 with 0.9% NaCl overnight followed by centrifugation at 13K for 10 min in a micro-centrifuge and the clear supernatant was taken. The resulting NPE-coated avidin had a protein conc. of 0.17 mg/ml and was coated with 28 residues of NPE per Avidin molecule.

Biotinylation of alkaline phosphatase

10mg of biotin and 10mg of N-hydroxysuccinimide (NHS) are weighed out into the same tube and 500ul of Dioxan is added. To this mixture is then added 8mg of 1,3-dicyclohexylcarbodiimide (DCC) in 500ul of Dimethylformamide (DMF). The solution is then left for 2.5 hours to react forming activated NHS-biotin esters. 100ul of the NHS-biotin solution was then added to 2ml of 1mg/ml AP in 0.1M bicarbonate and left overnight to react. After centrifugation (13K for 10min) and dialysis to remove uncoupled biotin, coating of the AP with biotin was confirmed by electrophoresis.

NPE-coated biotin-AP-avidin complexes were then generated by mixing 10ug of the NPE-coated avidin with 50ug of the AP-Biotin

ELISA

The wells of a microtitre plate were coated with 100ul of 0.0004ug/ml Avidin in coating buffer pH9.6 overnight at 4°C. After overnight incubation the plate was blocked (0.5%BSA in coating buffer) for 1 hour then washed three times with PBS-Tween.

Equal volumes of 10µg/ml Avidin-NPE and 50µg/ml Biotin AP were mixed to give a complex of final concentration 5ug/ml avidin-NPE/25ug/ml of biotin-AP. 10µl of this complex was then added to each well of the avidin coated ELISA plate. Half the plate was immediately irradiated with UV light for 3 minutes and the plate was incubated at 4°C for 2 hours. After washing, p-nitrophenyl phosphate substrate was added to each well and colour development was monitored at 405nm. An approx 5 fold increase in Avidin detection was obtained, with an OD 1.4 in irradiated wells compared to the unirradiated wells' OD of 0.32 after 20 minutes incubation. The proportional increase is even greater when the background value of OD 0.13 is subtracted from both values.

Sample Avidin Concentration	Non-illuminated	Illuminated
0.4pg/ml	0.19	1.27

Self-aggregating T-cell activation reagents

A murine anti-CD3 IgG and an anti-mouse IgG molecule may be separately coated, e.g. with NPE, before being conjugated to one another. The resulting conjugates are incapable of binding either to one another or to T cells. However after activation by irradiation, both the anti-IgG and anti-CD3 binding moieties are exposed. The resulting active conjugates will aggregate in solution by means of the IgG-anti-IgG interactions providing an extremely high local density of anti-CD3 sites capable of activating T cells.

This reagent may find application in the treatment of tumours, by stimulating T cell activation in their vicinity. The aggregate could be localised to the tumour via a further effector moiety capable of binding specifically to the tumour. Numerous variations are possible. For example the two antibodies could be

masked with different photoactivatable moieties, allowing activation of the aggregation and T cell stimulating functions separately by different wavelengths of light. Alternatively, one of the antibodies could be masked by a different mechanism requiring a different stimulus. for example aggregation could be prevented by a peptide cleavable by an enzyme (e.g. a metalloenzyme) known to be secreted by the tumour. Aggregation would then occur on contact with the enzyme, and the T cell stimulating function would be separately activatable by targeted irradiation.

Example 3

T-Cell activation

The murine anti-CD3 antibody OKT3 is coupled to Avidin by means of SPDP conjugation and the conjugate then coated with NPE as follows:

1-(2-nitrophenyl)ethoxycarbonylchloride (NPE-COCl) is prepared by dissolving 11mg of NPE (1-(2-nitrophenyl)ethanol) NPE in 250µl of dioxan followed by the addition of 5.6µl pyridine as catalyst and then 7.8µl diphosgene forming a white precipitate of the carbonylchloride. The solvent is then evaporated by nitrogen and the white solid resuspended in 250µl fresh dioxan. 12µl of this is then added to 0.5mg of the OKT3-Avidin conjugate, wrapped in foil and left on a rotating stirrer for two hours. The product is dialysed overnight against PBS and centrifuged at 10,000 rpm for 10 minutes to remove aggregated material. The NPE-coated conjugate is then exposed to a 10-fold calculated excess of biotin over the avidin binding capacity had the avidin not been NPE-conjugated. The excess biotin is then removed by dialysis.

After this blocking step, the NPE-coated conjugate is biotinylated by conventional methods, e.g. as described above in Example 2.

The CD4-positive T-cell line H9, which expresses CD3, is obtained from ETCC (European Tissue Culture Centre). The cells are cultured in RPMI medium and 10% foetal calf serum until confluent providing a suspension of ca 10^6 cells/ml. The cells are then
5 centrifuged at 1000 RPM for 5 minutes and re-suspended in medium (conditioned by previous OAW42 cell growth) at approximately half their original volume. 150 μ l aliquots, containing ca 300,000 cells, are delivered to each well of a sterile microtitre plate. 30 μ l of the conjugate to be tested, at a concentration of
10 0.1mg/ml, is added to the H9 cells at this stage. A series is illuminated with UV light, and a series left un-illuminated.

Those wells to be irradiated by exposure to UV-A light are irradiated through the plastic cover of the plate with a VL-206BL
15 UV-A lamp (2 x 6W tubes). The plate is then incubated for 3 hours at 37°C. The cells are then removed from the wells into Eppendorph tubes and centrifuged at 3000 RPM for 2 minutes. The cell supernatants are then decanted and IL-2 levels are then determined employing a sandwich ELISA kit (BD Biosciences, OptEIA
20 Human IL-2 Set), for which an IL-2 standard curve is previously obtained over the range 15.6pg/ml to 1000pg/ml IL-2.

Comparative experiments and controls plus and minus illumination are also run as follows:

25

- (1) As above but with an added excess of free biotin (to inhibit cross-linking);
- (2) no addition of NPE-conjugate;
- (3) addition of native OKT3-avidin conjugate instead of
30 biotinylated NPE-conjugate.

Good IL-2 production is found in those supernatants coming from cells exposed to the biotinylated NPE-conjugates illuminated by light.

35

*Example 4*5 *T-Cell Activation 2*

As an alternative to Example 3, both a monoclonal rat anti-mouse IgG antibody and the murine anti-CD3 monoclonal antibody OKT3 are separately coated with NPE employing 1-(2-nitrophenyl)ethoxycarbonylchloride (NPE-COCl) as in example 3. 10 Remaining free uncoated anti-mouse antibody is removed by specific absorption on a immunoaffinity column. The coated antibodies are then coupled to make a bispecific antibody and separated free from unconjugated antibodies. This light 15 activatable bispecific antibody is then used in place of the NPE-OKT3-Avidin construct of Example 3 to demonstrate light activation of T-cell activation.

Example 5

20

Use of Light-Activatable Construct in vivo

The light-activatable construct described in Example 4 can be used in *in vivo* T-cell activation as follows:

25

M5076 metastatic ovarian sarcoma is grown in BL6 mice. The tumour is subcutaneously transplanted into syngeneic animals as follows: the tumours are excised and diced as finely as possible in Hanks medium to provide a thick suspension 400 μ l of which is 30 mixed with 400 μ l of the construct (at 50 μ g/ml in Hanks medium) and then subcutaneously injected into the flank of the test animals. A separate group receives no added construct but only tumour.

35 Each group is then separated into two subgroups. One subgroup has no further manipulation, whereas the second has the skin around the subcutaneous injection irradiated with UV-A light (VL-

206BL UV-A lamp (2 x 6W tubes) with a total UV-A irradiance of ca. 16mW/cm² at a distance of 1cm.). After a number of weeks it will be seen that tumour growth is inhibited in the subgroup which have been given construct and been subjected to
5 irradiation.

Example 6

Use of zymogen conjugate

10

A monoclonal antibody is raised against the cleavage site produced on chymotrypsin when it is cleaved from chymotrypsinogen. The monoclonal antibody should not react with chymotrypsinogen itself.

15

Mice are immunised with chymotrypsin and hybridomas generated by conventional methods. The resulting hybridomas are then screened for those producing antibodies against the chymotrypsin but not against chymotrypsinogen. This is done by coating the wells of
20 microtitre plates with either chymotrypsin or chymotrypsinogen adding the candidate hybridoma supernatant culture fluid, allowing binding to occur, followed by the addition of a secondary labelled detector antibody. Those candidates giving rise to culture fluid which gives a significantly larger binding
25 of secondary detector antibody are further cloned, screened and grown up to produce useful amounts of the antibody.

30

The antibody is conjugated to chymotrypsinogen to form a "secondary conjugate", which can be used, e.g. in an immunoassay.

35

A "primary conjugate" is prepared by conjugating a detector antibody (directed against an antigen to be detected in the immunoassay) to both the antibody described above (reactive with chymotrypsin but not chymotrypsinogen) and to NPE-coated
35 chymotrypsin. This is achieved by first making a bispecific antibody comprising both detector antibody and anti-chymotrypsin

antibody, and then further conjugating NPE-inhibited chymotrypsin.

5 The immunoassay may be conducted in substantially conventional manner, e.g. in an ELISA plate having the analyte to be detected bound to it. After application and incubation of primary conjugate, unbound primary conjugate is washed from the plate and the secondary conjugate added.

10 The plate is then illuminated, activating the plate-bound chymotrypsin. The plate is incubated, during which time the chymotrypsin of the plate-bound primary conjugate acts on the chymotrypsinogen of the secondary conjugate to generate
15 chymotrypsin. This chymotrypsin may then be bound by the anti-chymotrypsin of the primary conjugate as well as the anti-chymotrypsin of secondary conjugate molecules, and can in turn catalyse the conversion of chymotrypsinogen to chymotrypsin in other secondary conjugate molecules. This leads to a chain
20 reaction of secondary conjugate activation and aggregation at those points on the surface of the plate at which primary conjugate is bound.

At a suitable time the reaction is stopped by removing the solution and washing the plate. The activity of chymotrypsin
25 remaining bound to the plate is determined by addition of a suitable substrate (e.g. N-benzoyl-L-tyrosine ethyl ester). From standards provided on the plate, unknown samples can be determined.

30 *Example 7*

An anti-Alkaline phosphatase antibody (Zymed) is cloaked with NPE as in Example 1 above.

A solution of Human Chorionic Gonadotrophin (HCG) of 1ng/ml is prepared in 50mM Tris buffer pH 7.4 and eleven five-fold serial
35 dilutions made. Duplicate 50µl aliquots of each of these, with a control blank of Tris buffer alone are then individually added

into microtitre wells (the duplicates being well-spaced from each other) and incubated for 1hr at room temperature in a humid chamber. The solutions are then shaken out and the wells washed four times with Tris Tween buffer.

- 5 50µl of a 1:250 dilution of a 1mg/ml anti-HCG antibody conjugated with alkaline phosphatase (Biogenis) is then added to each well, followed by 50µl of a solution of 10ng/ml NPE-conjugated anti-alkaline phosphatase antibody. Initial binding is allowed to take place by incubation for 30 minutes at room temperature in
- 10 the dark. Then one of each set of duplicate wells is illuminated with a VL-206BL UV-A lamp (2 x 6W tubes), and the plate further incubated for 15 minutes at room temperature. Following this the solutions are shaken out of the plate and the plate washed four times with Tris Tween. p-nitrophenyl phosphate substrate is
- 15 added to the wells and the optical density change is monitored at OD 405nm. It is seen that with the well diluted HCG samples the optical density change in the illuminated well set is more rapid than the non illuminated allowing faster and more sensitive detection.

20

Example 8

- A human anti-mouse IgG is cloaked with NPE employing 1-(2-nitrophenyl)ethoxycarbonylchloride (NPE-COCl) as in example 3
- 25 above, such that the antibody does not bind mouse IgG until illuminated.

- The CD4-positive T-cell line H9 is cultured in RPMI medium and 10% foetal calf serum until confluent. The cells are then
- 30 centrifuged at 1000 RPM for 5 minutes and re-suspended in medium (conditioned by previous OAW42 cell growth) at approximately half their original volume. 150µl aliquots, containing ca 300,000 cells, are delivered to each well of a sterile microtitre plate to provide two series of wells. Both receive either 20µl of an
- 35 equal mixture of OKT3 antibody and NPE-treated human anti-mouse antibody both at 0.1mg/ml or 20µl of 0.05mg/ml OKT3 antibody.

One series is illuminated by exposure to UV-A light by irradiation through the plastic cover of the plate with a VL-206BL UV-A lamp (2 x 6W tubes) and the other series left un-
5 illuminated.

The plate is then incubated for 3 hours at 37°C. The cells are then removed from the wells into Eppendorph tubes and centrifuged at 3000 RPM for 2 minutes. The cell supernatant solutions are
10 then decanted and IL-2 levels are then determined employing a sandwich ELISA kit (BD Biosciences, OptEIA Human IL-2 Set), for which an IL-2 standard curve is previously obtained over the range 15.6pg/ml to 1000pg/ml IL-2.

15 Those wells receiving both the NPE-treated human anti-mouse antibody and OKT3 plus illumination are found to produce more IL2 than the other wells.

While the invention has been described in conjunction with the
20 exemplary embodiments described above, many equivalent modifications and variations will be apparent to those skilled in the art when given this disclosure. Accordingly, the exemplary embodiments of the invention set forth are considered to be illustrative and not limiting. Various changes to the described
25 embodiments may be made without departing from the spirit and scope of the invention. All references cited herein are expressly incorporated by reference.

Claims:

1. A binding agent comprising two binding moieties, the binding moieties comprising

5

(i) a binding member, capable of binding to a binding partner, and

(ii) the binding partner,

10

one of said binding moieties being reversibly masked, whereby two such binding agents do not bind one another.

2. A binding agent according to claim 1 wherein the binding member and binding partner of a single binding agent cannot interact with one another after the binding moiety is unmasked.

15

3. A binding agent according to claim 2 wherein the binding partner and binding member are sterically incapable of interacting with one another.

20

4. A binding agent according to any one of claims 1 to 3 wherein the binding moiety is reversibly masked by a detachable masking element.

25

5. A binding agent according to claim 4 wherein the masking element is coupled to the binding agent via a selectively cleavable group or bond.

30

6. A binding agent according to claim 5 wherein the selectively cleavable group or bond is cleavable by irradiation, oxidation, reduction, pH change, or enzymatic cleavage.

7. A binding agent according to claim 6 wherein the irradiation is UV irradiation.

35

8. A binding agent according to claim 5 wherein the selectively cleavable group or bond is cleavable by a protease.

9. A binding agent according to claim 8 wherein cleavage of the selectively cleavable group or bond activates a protease activity of the binding agent.

5

10. A binding agent according to any one of claims 1 to 3 wherein said binding moiety may be unmasked by a conformational change in the binding agent.

10 11. A binding agent according to any one of claims 1 to 10 wherein the binding moieties are an antibody and its cognate epitope.

12. A binding agent according to any one of claims 1 to 10
15 wherein the binding moieties are avidin or streptavidin and biotin.

13. A binding agent according to any one of claims 1 to 12 further comprising an effector member.

20

14. A binding agent according to claim 13 wherein the effector member is a signal generating means.

15. A binding agent according to claim 14 wherein the signal
25 generating means is a label moiety or an enzyme.

16. A binding agent according to claim 13 wherein the effector member has a binding functionality.

30 17. A binding agent according to claim 16 wherein the effector member is capable of binding to a target cell type.

18. A binding agent according to claim 17 wherein the effector member is capable of binding to a tumour specific antigen or a
35 parasite antigen.

19. A binding agent according to claim 17 wherein the target cell is a cell of the immune system.

20. A binding agent according to claim 19 wherein the effector member is capable of activating said cell of the immune system.

21. A binding agent according to claim 20 wherein the cell is a T cell.

22. A binding agent according to claim 22 wherein the effector member is an anti-CD3 antibody.

23. A binding agent according to claim 13 wherein the effector member is an enzyme.

24. A binding agent according to claim 23 wherein the enzyme is capable of converting a prodrug to a active form.

25. A binding agent according to any one of claims 13 to 24 wherein the effector member is reversibly masked.

26. A binding agent according to any one of claims 13 to 25 wherein the effector member is unmasked by the same means as the binding member or partner.

27. A binding agent according to any one of claims 13 to 26 comprising at least two different effector members.

28. A binding agent according to any one of claims 1 to 27 for use in a method of medical treatment.

29. Use of a binding agent according to any one of claims 1 to 27 in the preparation of a medicament for the treatment of cancer.

30. A method of making a binding agent comprising the steps of:

(i) providing a first component comprising a binding member, capable of binding to a binding partner; and

(ii) providing a second component comprising said binding partner,

wherein one of said binding member and binding partner is reversibly masked such that said binding member or partner is prevented from binding to the other; and

iii) contacting said first component with said second component such that they become associated with one another.

31. A method according to claim 30 wherein the first and second components are covalently linked to one another.

32. A method according to claim 30 wherein the first and second components are non-covalently associated with one another.

33. A method according to claim 32 wherein the first and second components respectively comprise avidin/streptavidin and biotin.

34. A composition comprising at least two populations of binding agents, each population having at least two binding members for respective binding partners, each of said binding partners being present on another of said populations of binding agents, wherein a binding member of at least one of said populations is reversibly masked, whereby said one population does not bind the population carrying the respective binding partner.

35. A method of causing aggregation of a plurality of binding agents, comprising

providing a composition comprising at least two populations of binding agents, each population having at least two binding members for respective binding partners, each of said binding partners being present on another of said populations of binding agents, wherein a binding member of at least one of said

populations is reversibly masked, whereby said one population does not bind the population carrying the respective binding partner,

- 5 and unmasking said binding member, whereby said one population becomes capable of binding the population carrying the respective binding partner.

36. A kit comprising at least two populations of binding agents,
10 each population having at least two binding members for respective binding partners, each of said binding partners being present on another of said populations of binding agents, wherein a binding member of at least one of said populations is reversibly masked, whereby said one population does not bind the
15 population carrying the respective binding partner.

